Abstract
A growing body of data suggests that the glutamatergic system may be involved in the pathophysiology and treatment of severe mood disorders. Chronic treatment with the antimanic agents, lithium and valproate, resulted in reduced synaptic expression of the AMPA(-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptor subunit GluR1 in the hippocampus, while treatment with an antidepressant (imipramine) enhanced the synaptic expression of GluR1. The anticonvulsants, lamotrigine (6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine) and riluzole (2-amino-6-trifluoromethoxybenzothiazole), have been demonstrated to have efficacy in the depressive phase of bipolar disorder. We therefore sought to determine the role of these anticonvulsants, compared to that of the predominantly antimanic anticonvulsant valproate, on AMPA receptor localization. We found that the agents with a predominantly antidepressant profile, namely lamotrigine and riluzole, significantly enhanced the surface expression of GluR1 and GluR2 in a time- and dose-dependent manner in cultured hippocampal neurons. By contrast, the predominantly antimanic agent, valproate, significantly reduced surface expression of GluR1 and GluR2. Concomitant with the GluR1 and GluR2 changes, the peak value of depolarized membrane potential evoked by AMPA was significantly higher in lamotrigine- and riluzole-treated neurons, supporting the surface receptor changes. Phosphorylation of GluR1 at the PKA (cAMP-dependent protein kinase) site (S845) was enhanced in both lamotrigine- and riluzole-treated hippocampal neurons, but reduced in valproate-treated neurons. In addition, lamotrigine and riluzole, as well as the traditional antidepressant imipramine, also increased GluR1 phosphorylation at GluR1 (S845) in the hippocampus after chronic in vivo treatment. Our findings suggest that regulation of GluR1/2 surface levels and function may be responsible for the different clinical profile of anticonvulsants (antimanic or antidepressant), and may suggest avenues for the development of novel therapeutics for these illnesses.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ahmad S, Fowler LJ, Whitton PS (2004). Effects of acute and chronic lamotrigine treatment on basal and stimulated extracellular amino acids in the hippocampus of freely moving rats. Brain Res 1029: 41–47.
Alt A, Witkin JM, Bleakman D (2005). AMPA receptor potentiators as novel antidepressants. Curr Pharm Des 11: 1511–1527.
Banke TG, Bowie D, Lee H, Huganir RL, Schousboe A, Traynelis SF (2000). Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase. J Neurosci 20: 89–102.
Barria A, Derkach V, Soderling T (1997). Identification of the Ca2+/calmodulin-dependent protein kinase II regulatory phosphorylation site in the alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate-type glutamate receptor. J Biol Chem 272: 32727–32730.
Bazil CW (2002). New antiepileptic drugs. Neurologist 8: 71–81.
Bensimon G, Lacomblez L, Meininger V (1994). A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330: 585–591.
Black MD (2005). Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology (Berlin) 179: 154–163.
Boireau A, Dubedat P, Bordier F, Imperato A, Moussaoui S (2000). The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation. Neuropharmacology 39: 1016–1020.
Bonanno G, Giambelli R, Raiteri L, Tiraboschi E, Zappettini S, Musazzi L et al (2005). Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci 25: 3270–3279.
Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD (1999). A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 60: 79–88.
Carlezon Jr WA, Nestler EJ (2002). Elevated levels of GluR1 in the midbrain: a trigger for sensitization to drugs of abuse? Trends Neurosci 25: 610–615.
Choi KH, Clements RL, Greenshaw AJ (2005). Simultaneous AMPA/kainate receptor blockade and dopamine D(2/3) receptor stimulation in the nucleus accumbens decreases brain stimulation reward in rats. Behav Brain Res 158: 79–88.
Coyle JT, Duman RS (2003). Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 38: 157–160.
Derkach V, Barria A, Soderling TR (1999). Ca2+/calmodulin-kinase II enhances channel conductance of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate type glutamate receptors. Proc Natl Acad Sci USA 96: 3269–3274.
Donati RJ, Rasenick MM (2003). G protein signaling and the molecular basis of antidepressant action. Life Sci 73: 1–17.
Du J, Feng L, Yang F, Lu B (2000). Activity- and Ca(2+)-dependent modulation of surface expression of brain-derived neurotrophic factor receptors in hippocampal neurons. J Cell Biol 150: 1423–1434.
Du J, Gray NA, Falke C, Yuan P, Szabo S, Manji HK (2003). Structurally dissimilar antimanic agents modulate synaptic plasticity by regulating AMPA glutamate receptor subunit GluR1 synaptic expression. Ann NY Acad Sci 1003: 378–380.
Du J, Gray NA, Falke CA, Chen W, Yuan P, Szabo ST et al (2004). Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. J Neurosci 24: 6578–6589.
Ernst CL, Goldberg JF (2003). Antidepressant properties of anticonvulsant drugs for bipolar disorder. J Clin Psychopharmacol 23: 182–192.
Esteban JA, Shi SH, Wilson C, Nuriya M, Huganir RL, Malinow R (2003). PKA phosphorylation of AMPA receptor subunits controls synaptic trafficking underlying plasticity. Nat Neurosci 6: 136–143.
Evins AE (2003). Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. J Clin Psychiatry 64 (Suppl 8): 9–14.
Gray NA, Du J, Falke CS, Yuan P, Manji HK (2003). Lithium regulates total and synaptic expression of the AMPA glutamate receptor GluR2 in vitro and in vivo. Ann NY Acad Sci 1003: 402–404.
Groeneveld GJ, Van Kan HJ, Kalmijn S, Veldink JH, Guchelaar HJ, Wokke JH et al (2003). Riluzole serum concentrations in patients with ALS: associations with side effects and symptoms. Neurology 61: 1141–1143.
Hayashi Y, Shi SH, Esteban JA, Piccini A, Poncer JC, Malinow R (2000). Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction. Science 287: 2262–2267.
Hirsch LJ, Weintraub D, Du Y, Buchsbaum R, Spencer HT, Hager M et al (2004). Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 63: 1022–1026.
Kaddis FG, Uretsky NJ, Wallace LJ (1995). DNQX in the nucleus accumbens inhibits cocaine-induced conditioned place preference. Brain Res 697: 76–82.
Kendell SF, Krystal JH, Sanacora G (2005). GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin Ther Targets 9: 153–168.
Knapp RJ, Goldenberg R, Shuck C, Cecil A, Watkins J, Miller C et al (2002). Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur J Pharmacol 440: 27–35.
Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G et al (2002). Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry 7 (Suppl 1): S71–S80.
Kwan P, Brodie MJ (2001). Effectiveness of first antiepileptic drug. Epilepsia 42: 1255–1260.
Lee HK, Barbarosie M, Kameyama K, Bear MF, Huganir RL (2000). Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity. Nature 405: 955–959.
Lee HK, Kameyama K, Huganir RL, Bear MF (1998). NMDA induces long-term synaptic depression and dephosphorylation of the GluR1 subunit of AMPA receptors in hippocampus. Neuron 21: 1151–1162.
Lees G, Leach MJ (1993). Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex. Brain Res 612: 190–199.
Li X, Tizzano JP, Griffey K, Clay M, Lindstrom T, Skolnick P (2001). Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 40: 1028–1033.
Li Y, Vartanian AJ, White FJ, Xue CJ, Wolf ME (1997). Effects of the AMPA receptor antagonist NBQX on the development and expression of behavioral sensitization to cocaine and amphetamine. Psychopharmacology (Berlin) 134: 266–276.
Malenka RC (2003). Synaptic plasticity and AMPA receptor trafficking. Ann NY Acad Sci 1003: 1–11.
Malinow R, Malenka RC (2002). AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci 25: 103–126.
Mammen AL, Kameyama K, Roche KW, Huganir RL (1997). Phosphorylation of the alpha-amino-3-hydroxy-5-methylisoxazole4-propionic acid receptor GluR1 subunit by calcium/calmodulin-dependent kinase II. J Biol Chem 272: 32528–32533.
Manji HK, Lenox RH (2000). Signaling: cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry 48: 518–530.
Ossowska K, Pietraszek M, Wardas J, Wolfarth S (2004). Potential antipsychotic and extrapyramidal effects of (R,S)-3,4-dicarboxyphenylglycine [(R,S)-3,4-DCPG], a mixed AMPA antagonist/mGluR8 agonist. Pol J Pharmacol 56: 295–304.
Roche KW, O'Brien RJ, Mammen AL, Bernhardt J, Huganir RL (1996). Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron 16: 1179–1188.
Rogawski MA, Loscher W (2004). The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 10: 685–692.
Rumpel S, LeDoux J, Zador A, Malinow R (2005). Postsynaptic receptor trafficking underlying a form of associative learning. Science 308: 83–88.
Shao L, Young LT, Wang JF (2005). Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry 58: 879–884.
Smith KE, Gibson ES, Dell'Acqua ML (2006). cAMP-dependent protein kinase postsynaptic localization regulated by NMDA receptor activation through translocation of an A-kinase anchoring protein scaffold protein. J Neurosci 26: 2391–2402.
Sun X, Zhao Y, Wolf ME (2005). Dopamine receptor stimulation modulates AMPA receptor synaptic insertion in prefrontal cortex neurons. J Neurosci 25: 7341–7351.
Svenningsson P, Tzavara ET, Witkin JM, Fienberg AA, Nomikos GG, Greengard P (2002). Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci USA 99: 3182–3187.
Szymczyk G, Zebrowska-Lupina I (2000). Influence of antiepileptics on efficacy of antidepressant drugs in forced swimming test. Pol J Pharmacol 52: 337–344.
Vanover KE (1998). Effects of AMPA receptor antagonists on dopamine-mediated behaviors in mice. Psychopharmacology (Berlin) 136: 123–131.
Wolf ME, Sun X, Mangiavacchi S, Chao SZ (2004). Psychomotor stimulants and neuronal plasticity. Neuropharmacology 47: 61–79.
Zarate Jr CA, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D et al (2004). An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 161: 171–174.
Zarate Jr CA, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA et al (2005). An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 57: 430–432.
Acknowledgements
We acknowledge the support of the Intramural Research Program of the National Institute of Mental Health and the Stanley Medical Research Institute. Holly Giesen provided outstanding editorial assistance.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Neuropsychopharmacology website (http://www.nature.com/npp)
Supplementary information
Rights and permissions
About this article
Cite this article
Du, J., Suzuki, K., Wei, Y. et al. The Anticonvulsants Lamotrigine, Riluzole, and Valproate Differentially Regulate AMPA Receptor Membrane Localization: Relationship to Clinical Effects in Mood Disorders. Neuropsychopharmacol 32, 793–802 (2007). https://doi.org/10.1038/sj.npp.1301178
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1301178
Keywords
This article is cited by
-
Electrochemical detection of the neurotransmitter glutamate and the effect of the psychotropic drug riluzole on its oxidation response
Analytical and Bioanalytical Chemistry (2024)
-
Echinacoside exhibits antidepressant-like effects through AMPAR–Akt/ERK–mTOR pathway stimulation and BDNF expression in mice
Chinese Medicine (2022)
-
Decreased efficacy of the ketamine and scopolamine-induced sustained antidepressant-like effects in rats receiving metformin
Pharmacological Reports (2022)
-
Modulation of DNA Methylation and Gene Expression in Rodent Cortical Neuroplasticity Pathways Exerts Rapid Antidepressant-Like Effects
Molecular Neurobiology (2021)
-
Excitatory and inhibitory synaptic dysfunction in mania: an emerging hypothesis from animal model studies
Experimental & Molecular Medicine (2018)
